Differences in systemic adaptive immunity contribute to the ‘frequent exacerbator’ COPD phenotype

Respiratory Research

Table 3 Flow cytometry absolute number of cells results from COPD patients susceptible to frequent vs. infrequent exacerbations

Cell type	FE (n = 8) Mean abs No. ± SD/Median abs No. (IQR) *10^6/ml	IE (n = 16) Mean abs No. ± SD/Median abs No. (IQR) *10^6/ml	p
CD3+	1.33 ± 0.38	1.42 ± 0.53	0.665
CD4+	0.91 ± 0.19	1.07 ± 0.42	0.223
CD4+ HLA-DR+	0.05 (0.02–0.07)	0.03 (0.02–0.04)	0.490
CD4+ PD-1+	0.27 ± 0.09	0.28 ± 0.14	0.785
CD4+ Naive	0.34 ± 0.12	0.38 ± 0.21	0.505
CD4+ Tcm	0.17 ± 0.05	0.25 ± 0.12	0.035
CD4+ Tem	0.23 ± 0.12	0.26 ± 0.14	0.669
CD4+ Tem PD-1+	0.14 ± 0.07	0.13 ± 0.07	0.666
CD4+ End	0.17 ± 0.06	0.17 ± 0.11	0.826
CD8+	0.28 (0.13–53)	0.30 (0.13–0.40)	0.697
CD8+ HLA-DR+	0.05 (0.01–0.09)	0.03 (0.01–0.06)	0.653
CD8+ PD-1+	0.12 ± 0.09	0.11 ± 0.07	0.707
CD8+ Naïve	0.04 ± 0.02	0.04 ± 0.03	0.662
CD8+ Tcm	0.05 (0.02–0.06)	0.04 (0.02–0.07)	0.976
CD8+ Tem	0.16 ± 0.12	0.11 ± 0.07	0.368
CD8+ Tem HLA-DR+	0.02 ± 0.01	0.03 ± 0.06	0.759
CD8+ End	0.13 ± 0.05	0.09 ± 0.06	0.575
Treg	0.06 ± 0.03	0.08 ± 0.04	0.173
Treg PD-1+	0.02 ± 0.01	0.03 ± 0.01	0.296
NK	0.51 ± 0.24	0.30 ± 0.17	0.336
NK CD56^bright	0.01 ± <0.01	0.01 ± <0.01	0.572
NK CD56^dim	0.39 ± 0.12	0.18 ± 0.14	0.373
NK CD56^brightCD16^dim	0.01 (<0.01–0.02)	0.01 (<0.01–0.01)	0.490
NK CD56^dimCD16^bright	0.35 ± 0.14	0.15 ± 0.13	0.398
NK CD56 + CD56^bright	0.02 (0.01–0.03)	0.01 (<0.01–0.02)	0.653
NK CD56 + CD56^dim	0.29 (0.21–0.49)	0.26 (0.12 0.41)	0.490
iNKT	0.02 (0.01–0.03)	0.01 (0.01–0.03)	0.214
γδ T	0.01 (<0.01–0.02)	<0.01 (<0.01–0.01)	0.153
γδ T CD56+	0.01 ± 0.01	0.01 ± 0.01	0.544

Table shows the absolute number of cells in 1 ml of peripheral blood. Significance was calculated using t test or Mann-Whitney U test as appropriate. Abs No. absolute number, PD-1+ cell marker for programmed cell death, End end-stage T cell, Treg regulatory T cell, NK natural killer, iNKT invariant natural killer T cell

ISSN: 1465-993X